Amylyx Pharmaceuticals, Inc. (AMLX): Total Assets
$332.64M
As of 2025-12-31
$264.56M
As of 2026-06-30
-5.3%
3-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $332.64M | +71.8% | 2026-03-03, Balance as of period end |
| 2024-12-31 | $193.63M | -62.6% | 2026-03-03, Balance as of period end |
| 2023-12-31 | $517.45M | +32.2% | 2025-03-04, Balance as of period end |
| 2022-12-31 | $391.45M | +270.6% | 2024-02-22, Balance as of period end |
| 2021-12-31 | $105.61M | n/a | 2023-03-13, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Amylyx Pharmaceuticals, Inc. (AMLX) | 2025-12-31 | $332.64M | +71.8% |
| Abbott Laboratories (ABT) | 2025-12-31 | $86.71B | +6.5% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $90.04B | -2.8% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $37.66M | -3.0% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $112.48B | +42.9% |
| Pfizer Inc (PFE) | 2025-12-31 | $208.16B | -2.5% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $199.21B | +10.6% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $261.15M | +8.4% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $136.87B | +16.9% |
Compare AMLX, ABT, BMY, TXMD side by side · Screen every company in Pharmaceutical Preparations ↗